Johnson & Johnson Reports Long-Term Data on Myasthenia Drug
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) recently reported new Phase 3 data showing sustained symptom improvement and reduced antibody levels in patients with generalized myasthenia gravis treated with …
Johnson & Johnson Reports Long-Term Data on Myasthenia Drug Read More